2Guidelines Subcommittee. 1999 world health organization - international society of the human insulin receptor by the antidia - btic drugmetformix. J Hypertens, 1999,17(2) : 151 ～ 183.
1Sutton SJM, Rendell M, Pandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic cantrol in patients with type 2 diabetes [ J]. Diabetes Care, 2002, 25 ( 11 ) :2058-64,.
2Purrello F, Rabuazza AM. Metabolic factors that affect beta-cell function and survival[J]. Diabet Nutr Metab,2000;13:84-91.
3Scheen A J, Lefebvere PJ. Oral anti-diabetic agents: a guide to selection[J]. Drugs,1998 ;55(2) :225-36.
4Garber A J, Duncan TG, Goodman AM, et al. Efficacy of metformin in type 2 diabetes : results of a double-blind, placebo-controlled, dose-response trial[ J]. AJMN, 1997 ; 103:491-7.
7Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens , 1993, 11(3): 309-317.
8Viberti G, Kahn SE, Greene DA, et al . A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care , 2002, 25(10): 1737-1743.
9The Sixth Report of the Joint National Committee on prevention, detection, and treatment of high blood pressure. Arch Intern Med , 1997, 157: 2413-2446.
101999 World Health Organization-International Society of Hypertension Guideline for the Management of Hypertension. Guidelines Subcommittee. J Hypertens , 1999, 17: 151-183.
